硼替佐米体外对前列腺癌细胞迁移和侵袭的影响及其机制

目的：探讨硼替佐米体外对前列腺癌细胞迁移和侵袭的影响及其机制。方法：选择对数生长的LNCAP前列腺癌细胞株，分别选择不同浓度的硼替佐米处理，在处理24h后进行前列腺癌细胞迁移和侵袭的检测，同时收集细胞进行炎症因子表达实验和Western blot检测分析。结果：LNCAP+硼替佐米(10nmol/L)组、LNCAP+硼替佐米(20nmol/L)组细胞的迁移指数与侵袭指数都明显低于对单独LNCAP组，并且IL-12及TNF-α表达量明显低于单独LNCAP组，对比差异都有统计学意义(P<0.05)不同浓度的硼替佐米处理LNCAP细胞24h后，FAK总蛋白无明显变化，对比差异都无统计学意义(P>0.05)。结论：替佐米能够有效的抑制前列腺癌LNCAP细胞的迁移和侵袭，其作用的发挥与抑制IL-12及TNF-α的表达分泌有关，但对FAK总蛋白的表达无影响。

The mechanism of bortezomib on prostate cancer cell in vitro in migration and invasion effects

  Objective: To investigate the migration and invasion effects and its mechanism of bortezomib on prostate cancer cell in vitro. Methods: Selected LNCAP logarithmic growth of prostate cancer cell lines, given with different levels of bortezomib treatment. After 24h, the migration and invasion of prostate cancer were detected, and we collected cells for expression of inflammatory cytokines experiments and Western blot analysis. Results: The cell migration index and invasion index of the LNCAP + bortezomib (10nmol / L) group and LNCAP + bortezomib (20nmol / L) group were significantly lower than for individual LNCAP group, and the IL-12 and TNF-α expression levels were also significantly lower than single LNCAP group, compared to the differences were statistically significant (P <0.05). When  given the different levels of bortezomib treatment in the LNCAP cells after 24h, The total protein FAK changes showed no significant data (P> 0.05). Conclusion: Bortezomib can effectively inhibit the migration and invasion of prostate cancer cells, and it may  inhibite the expression of IL-12 and TNF-αbut it had no effect on the expression of total FAK protein.